Astaxanthin improves glucose metabolism and reduces blood pressure in patients with type 2 diabetes mellitus

Asia Pac J Clin Nutr. 2018;27(2):341-346. doi: 10.6133/apjcn.052017.11.


Background and objectives: This randomized, placebo-controlled trial was performed for 8 weeks to investigate the potential effects of astaxanthin (AST) supplementation on the adiponectin concentration, lipid peroxidation, glycemic control, insulin sensitivity, and anthropometric indices in participants with type 2 diabetes mellitus.

Methods and study design: We enrolled 44 participants with type 2 diabetes who met our inclusion criteria. Eight milligrams of AST supplementation or a placebo were randomly administered once daily for 8 weeks to these participants.

Results: The 8-week administration of AST supplementation increased the serum adiponectin concentration and reduced visceral body fat mass (p<0.01), serum triglyceride and very-low-density lipoprotein cholesterol concentrations, and systolic blood pressure (p<0.05). Furthermore, AST significantly reduced the fructosamine concentration (p<0.05) and marginally reduced the plasma glucose concentration (p=0.057).

Conclusions: We demonstrated that because participants with type 2 diabetes often have hypertriglycemia and uncontrolled glucose metabolism; our findings of dual beneficial effects are clinically valuable. Our results may provide a novel complementary treatment with potential impacts on diabetic complications without adverse effects.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adiponectin / metabolism
  • Antioxidants / pharmacology
  • Blood Glucose / drug effects
  • Blood Pressure / drug effects*
  • Diabetes Mellitus, Type 2 / blood*
  • Double-Blind Method
  • Female
  • Glucose / metabolism*
  • Humans
  • Lipid Peroxidation / drug effects
  • Male
  • Middle Aged
  • Xanthophylls / pharmacology


  • Adiponectin
  • Antioxidants
  • Blood Glucose
  • Xanthophylls
  • astaxanthine
  • Glucose